Home›Trial›NCT05536804
🔬NCT05536804Phase 2ACTIVE NOT RECRUITING

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Study Summary

We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.

Conditions
OverweightObesityChronic Kidney DiseaseType 2 DiabetesT2D
Interventions / Drugs
TirzepatidePlacebo
View on ClinicalTrials.gov ↗
Sponsor
LLY
Eli Lilly and Company
Diabetes/Oncology
C53/100
Study Details
Enrollment140 participants
Primary Completion—
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.865822+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.